Endotypes are characterized by the immunological, inflammatory, metabolic, and remodelling pathways that explain the mechanisms underlying the clinical presentation (phenotype) of a disease. Recessive dystrophic epidermolysis bullosa (RDEB) is a severe blistering disease caused by COL7A1 pathogenic variants. Although underscored by animal studies, the endotypes of human RDEB are poorly understood. To fill this gap, we apply systems immunology approaches using single-cell high-dimensional techniques to capture the signature of peripheral immune cells and the diversity of metabolic profiles in RDEB adults, sampled outside of any opportunistic infection and active cancer. Our study, demonstrates the particular inflammation and immunity characteristics of RDEB adults, with activated / effector T and dysfunctional natural killer cell signatures, concomitant with an overall pro-inflammatory lipid signature. Artificial intelligence prediction models and principal component analysis stress that RDEB is not solely confined to cutaneous issues but has complex systemic endotypes marked by immune dysregulation and hyperinflammation. By characterising the phenotype-endotype association in RDEB adults, our study lays the groundwork for translational interventions that could by lessening inflammation, alleviate the everlasting suffering of RDEB patients, while awaiting curative genetic therapies.

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41467-025-55934-7DOI Listing

Publication Analysis

Top Keywords

rdeb adults
12
systems immunology
8
recessive dystrophic
8
dystrophic epidermolysis
8
epidermolysis bullosa
8
rdeb
7
immunology integrates
4
integrates complex
4
endotypes
4
complex endotypes
4

Similar Publications

Systems immunology integrates the complex endotypes of recessive dystrophic epidermolysis bullosa.

Nat Commun

January 2025

National Institute of Health and Medical Research (INSERM) UMRS-976 HIPI, Paris Cité University, Saint-Louis Hospital, 75010, Paris, France.

Endotypes are characterized by the immunological, inflammatory, metabolic, and remodelling pathways that explain the mechanisms underlying the clinical presentation (phenotype) of a disease. Recessive dystrophic epidermolysis bullosa (RDEB) is a severe blistering disease caused by COL7A1 pathogenic variants. Although underscored by animal studies, the endotypes of human RDEB are poorly understood.

View Article and Find Full Text PDF
Article Synopsis
  • Patients with recessive dystrophic epidermolysis bullosa (RDEB) often suffer from neuropathic pain and itch, but there is limited evidence on effective treatments for these symptoms.
  • A randomized, double-blinded crossover trial was conducted to evaluate the efficacy of pregabalin (50-300 mg/d) compared to a placebo in treating these symptoms in RDEB patients aged 8 to 40.
  • The study included 10 participants who received both treatments in a randomized order, and the main outcome measured was the difference in pain and itch scores using a visual analog scale before and after the interventions.
View Article and Find Full Text PDF
Article Synopsis
  • Pain is a significant issue for individuals with epidermolysis bullosa (EB), impacting their quality of life and identified as a priority for improved treatments.
  • The Prospective EB Longitudinal Evaluation Study (PEBLES) gathered data over eight years from 61 participants to evaluate pain characteristics and treatments in different RDEB subtypes.
  • Results showed that 93% of participants experienced pain, with a median background pain score of 40 and procedural pain score of 52; many did not use medication for pain management despite its severity.
View Article and Find Full Text PDF

Patients with recessive dystrophic epidermolysis bullosa (RDEB) experience numerous complications, which are exacerbated by inflammatory dysregulation and infection. Understanding the immunological mechanisms is crucial for selecting medications that balance inflammation control and immunocompetence. In this cross-sectional study, aiming to identify potential immunotherapeutic targets and inflammatory biomarkers, we delved into the interrelationship between clinical severity and systemic inflammatory parameters in a representative RDEB cohort.

View Article and Find Full Text PDF

Genetic testing is the gold standard for diagnosing different epidermolysis bullosa (EB) subtypes; however, testing rates are low. We conducted a pilot study to test feasibility of a novel, home-based registry that involved patients with EB submitting self-reported clinical symptoms using secure, online surveys (REDCap) and submitting buccal swabs for exome sequencing of EB-related genes (GeneDx). In total, 50 EB participants were enrolled, with an average age of 17 years and an average distance of 198 miles from EB specialty centers.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!